journal article·2022-12Open access

Brain‐Targeting Metastatic Tumor Cell Membrane Cloaked Biomimetic Nanomedicines Mediate Potent Chemodynamic and RNAi Combinational Therapy of Glioblastoma

Dongya Zhang, Yajing Sun, Shiyu Wang, Yan Zou, Meng Zheng, Bingyang Shi

Advanced Functional Materials· Volume 32· Issue 51

Abstract

Abstract The complex genetic heterogeneity of glioblastoma (GBM) together with the existence of blood brain barrier (BBB) renders GBM essentially incurable. In this paper, a brain‐targeting metastatic tumor cell membrane cloaked biomimetic nanomedicine that potently induces cascade chemodynamic and RNA interference (RNAi) is developed for combinational GBM therapy. The designed nanomedicines are constructed from metastatic melanoma cell membrane, charge‐conversional middle layer, and siRNA complexed polyethyleneimine xanthate (PEX). PEX chelates the abundant copper ions in tumor cells and then reacts with intracellular glutathione (GSH), resulting in GSH depletion and the reduction of Cu2+ to Cu+, followed by reacting with H2O2 and producing •OH via Fenton‐like reaction. Interestingly, the acidic conditions in endo/lysosomes accelerate siRNA release, inducing potent gene silencing of the anti‐apoptotic B‐cell lymphoma 2 (Bcl‐2), lead to multiple molecular cascades that readily induces GBM cell apoptosis. The results also demonstrate that this nanomedicine exhibits efficient BBB penetration via decreasing the tightness and interacting with the adhesion molecules in endothelial cells. More importantly, improved therapeutic efficacy with extended survival rates are achieved in both local melanoma and orthotopic GBM tumor models, suggesting that the chemodynamic and gene combinatorial therapy mediated by the biomimetic nanomedicines shows promising potential in treating GBM and brain metastases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Henan‐Macquarie Uni Joint Centre for Biomedical Innovation School of Life Sciences Henan University Kaifeng Henan 475004 China

Henan Key Laboratory of Brain Targeted Bio‐nanomedicine School of Life Sciences Henan University Kaifeng Henan 475004 China

Maquarie Medical School Faculty of Medicine, Health and Human Sciences Macquarie University Sydney NSW 2109 Australia

Funding

National Natural Science Foundation of China · Science and Technology Innovation Talents in Universities of Henan Province · Key Technologies Research and Development Program

References (61)

Show source-provided references
1. 10.3322/caac.2161310.3322/caac.21613 ↗
2. 10.1038/s41571-018-0003-510.1038/s41571-018-0003-5 ↗
3. 10.1001/jama.2017.1871810.1001/jama.2017.18718 ↗
4. 10.1002/adfm.20210686010.1002/adfm.202106860 ↗
5. 10.1038/s41578-019-0135-y10.1038/s41578-019-0135-y ↗
6. 10.18632/aging.10141510.18632/aging.101415 ↗
7. 10.1016/j.nantod.2020.10094610.1016/j.nantod.2020.100946 ↗
8. 10.1002/adma.20190602410.1002/adma.201906024 ↗
9. Lin L.‐S. · J. Am. Chem. Soc. · 2019 · 141 · 9945
10. 10.1002/adfm.20211225110.1002/adfm.202112251 ↗
11. 10.1002/EXP.2021023810.1002/EXP.20210238 ↗
12. Lin L. S. · Angew. Chem. Int. Edit · 2018 · 130 · 5000
13. Hu Y. · Nano Lett. · 2019 · 19 · 2738
14. Cao C. · Chem. Sci. · 2022 · 13 · 889
15. 10.7150/thno.2984010.7150/thno.29840 ↗
16. 10.1158/1535-7163.MCT-18-066710.1158/1535-7163.MCT-18-0667 ↗
17. 10.1016/j.bcp.2020.11409810.1016/j.bcp.2020.114098 ↗
18. Liu C. · ACS Nano · 2019 · 13 · 4277
19. Ma B. · J. Am. Chem. Soc. · 2019 · 141 · 857
20. 10.1016/j.jhazmat.2020.12273510.1016/j.jhazmat.2020.122735 ↗
21. 10.1016/j.jhazmat.2020.12435110.1016/j.jhazmat.2020.124351 ↗
22. 10.1016/j.biomaterials.2020.12016710.1016/j.biomaterials.2020.120167 ↗
23. 10.1016/j.ccr.2020.21361010.1016/j.ccr.2020.213610 ↗
24. Hao Y.‐N. · J. Mater. Chem. B · 2021 · 9 · 266
25. 10.1002/adfm.20210024310.1002/adfm.202100243 ↗
26. 10.1002/EXP.2021001010.1002/EXP.20210010 ↗
27. 10.3390/cancers1108119110.3390/cancers11081191 ↗
28. Liu Y. · ACS Nano · 2018 · 12 · 4893
29. 10.1038/s41580-018-0089-810.1038/s41580-018-0089-8 ↗
30. 10.1038/ncomms1607810.1038/ncomms16078 ↗
31. 10.1016/j.canlet.2018.11.02710.1016/j.canlet.2018.11.027 ↗
32. He W. · ACS Nano · 2022 · 16 · 6308
33. 10.1002/smll.20200089710.1002/smll.202000897 ↗
34. 10.1016/j.nantod.2021.10132510.1016/j.nantod.2021.101325 ↗
35. 10.1023/A:100632941043310.1023/A:1006329410433 ↗
36. 10.1007/s00401-011-0933-910.1007/s00401-011-0933-9 ↗
37. 10.1021/acsnano.9b0439710.1021/acsnano.9b04397 ↗
38. Tang W. · Chem. Soc. Rev. · 2019 · 48 · 3014
39. 10.1002/adfm.20190936910.1002/adfm.201909369 ↗
40. 10.1038/s41568-019-0220-y10.1038/s41568-019-0220-y ↗
41. 10.1158/1078-0432.CCR-18-162410.1158/1078-0432.CCR-18-1624 ↗
42. Liu Y. · Nano Lett. · 2020 · 20 · 1646
43. 10.1016/j.biomaterials.2019.01.00710.1016/j.biomaterials.2019.01.007 ↗
44. 10.1002/adfm.20200434610.1002/adfm.202004346 ↗
45. 10.1002/EXP.2021017110.1002/EXP.20210171 ↗
46. 10.1002/EXP.2021027410.1002/EXP.20210274 ↗
47. Fang R. H. · Nano Lett. · 2014 · 14 · 2188
48. 10.1002/anie.20161192710.1002/anie.201611927 ↗
49. Chen Z. · ACS Nano · 2016 · 10 · 10057
50. 10.1111/bph.1477310.1111/bph.14773 ↗
51. 10.1016/j.jconrel.2021.06.01510.1016/j.jconrel.2021.06.015 ↗
52. 10.1016/j.biomaterials.2020.12042910.1016/j.biomaterials.2020.120429 ↗
53. 10.1038/s41590-019-0561-410.1038/s41590-019-0561-4 ↗
54. Sun J. · Angew. Chem., Int. Ed. · 2020 · 59 · 12128
55. Yang Y. · Nano Lett. · 2018 · 18 · 6875
56. 10.1021/acsnano.0c0516910.1021/acsnano.0c05169 ↗
57. 10.1002/advs.20190169010.1002/advs.201901690 ↗
58. 10.1002/adbi.20160000910.1002/adbi.201600009 ↗
59. 10.1186/s12943-022-01516-w10.1186/s12943-022-01516-w ↗
60. 10.1038/s41582-018-0025-810.1038/s41582-018-0025-8 ↗
61. Nduom E. K. · Neuro‐Oncology · 2015 · 17 · 14